Skip to main content
Industry News
FDA OKs UCB's epilepsy nasal spray

UCB's Nayzilam, or midazolam, nasal spray has been approved by the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that differ from usual seizure patterns in patients with epilepsy who are at least 12 years old. A late-stage study demonstrated treatment was associated with higher likelihood of seizure termination within 10 minutes of dosing and the absence of recurrence within six hours of initial dosing, compared with placebo.

Full Story: